Fairvalue-Calculator Fairvalue-Calculator
EN DE

APT Medical Inc (688617) Fair Value & Analysis

Healthcare · CN · Market cap 29.0B CNY

Price¥189.60
Fair Value¥113.16
Upside-40.3%
Quality92/100
Evidence: High Range ¥87.07 – ¥287.76

Analysis

APT Medical Inc (688617) currently trades at ¥189.60, while our model-based Fair Value estimate is ¥113.16 — implying the stock looks roughly 40.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China. It offers electrophysiology products, such as navigation systems, navigated catheters, mapping catheters, ablation catheters, transseptal needles and sheaths, and steerable sheaths; and interventional cardiology and peripheral products, including access, diagnostic products, therapeutic products, and accessories. The company also manufactures and supplies EP and vascular intervention medical devices. In addition, it provides OEM and ODM services comprising project design and development, customization, and volume OEM; and customized products consisting of catheters, guidewires, and delivery systems, as well as nitinol products in cardiology, peripheral, neurology, and urology. APT Medical Inc. was founded in 2002 and is headquartered in Shenzhen, China.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -84% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.